Objective:
To evaluate the efficacy and safety of EYP-1901 in treating retinal exudative diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME).
Key Findings:
- EYP-1901 met primary endpoint in DAVIO 2, showing non-inferiority to aflibercept based on BCVA change.
- Over 85% of EYP-1901-treated patients had stable or improved vision at six months.
- In VERONA, EYP-1901 showed extended time to first supplemental treatment compared to aflibercept.
- EYP-1901 demonstrated early and sustained vision improvements in DME patients.
Interpretation:
Limitations:
- EYP-1901 is still investigational and not authorized for sale.
- Long-term safety and efficacy data are pending from ongoing phase 3 trials.
Conclusion:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
